$3,000.00
PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Explore and visualize revenue dynamics in Shire’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.
CONTENTS
6 OVERVIEW
6 Snapshot
6 Model updates
7 Analysis structure
8 Q2 2018 REVIEW
8 Shire’s earnings edge higher after agreeing to sale to Takeda
8 Immunology sales drive
8 Hematology business remains solid for now
8 Neuroscience and internal medicine business
9 Oncology and ophthalmology progress
9 Bibliography
10 Q1 2018 REVIEW
10 Shire reports a solid start to 2018 amid talk of a takeover by Takeda
10 $65bn takeover by Takeda
11 Key Q1 2018 events
11 Bibliography
12 Q4 2017 REVIEW
12 Shire reports 8% product revenue growth in 2017
12 Immunology business
12 Cinryze revenues rebound as Shire mitigates HAE headwinds
13 AB Biosciences deal to boost immunoglobin R&D
14 SHP609 failure in Hunter syndrome
14 Neuroscience business
15 Hematology business
15 Internal medicines
16 Ophthalmology business
16 Key catalysts for 2018
17 Bibliography
18 Q3 2017 REVIEW
18 Cinryze supply issues hold Shire to flat revenues
19 Neuroscience business
19 Ophthalmology
19 Q3 2017 events
20 Bibliography
21 STRATEGY ANALYSIS
21 Acquisitions over 2015–16
21 2018 will continue to focus on execution restructure
22 Big increase in net debt is not a large concern
24 Takeda takeover
24 Shire’s SWOT analysis
25 Shire’s key events and catalysts
26 Bibliography
28 PORTFOLIO ANALYSIS
32 Q2 2018
35 FACTS AND FIGURES
35 Shire’s prescription pharma sales outlook
35 Shire’s regional pharma sales outlook
38 Shire’s therapy area dynamics
50 Shire’s growth drivers and resistors
54 Shire’s portfolio lifecycle analysis
56 Shire’s pipeline analysis
58 Shire’s M&A strategy and history
62 Bibliography
LIST OF FIGURES
35 Figure 1: Shire’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
38 Figure 2: Shire’s therapy area dynamics, 2017–27
54 Figure 3: Shire’s launch/core/expiry portfolio configuration, 2017–27
56 Figure 4: Shire’s pipeline overview
LIST OF TABLES
23 Table 1: Shire’s historical net debt to EBITDA comparison
29 Table 2: Shire’s sales by therapy area ($m), 2017–27
37 Table 3: Shire’s prescription pharmaceutical sales by region ($m), 2017–27
39 Table 4: Shire’s sales by therapy area ($m), 2017–27
42 Table 5: Shire’s central nervous system portfolio sales, by product ($m), 2017–27
44 Table 6: Shire’s rare diseases portfolio sales, by product ($m), 2017–27
47 Table 7: Shire’s hematology portfolio sales, by product ($m), 2017–27
49 Table 8: Shire’s ophthalmology portfolio sales, by product ($m), 2017–27
51 Table 9: Shire’s key products, 2017–27
55 Table 10: Shire’s sales by launch, core, and expiry portfolio ($m), 2017–27
57 Table 11: Shire’s launch portfolio sales, by product ($m), 2017–27
59 Table 12: Shire’s key merger and acquisition deals, 2001–18
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!